A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia

  • Bong Ki Lee
  • , Byeong Keuk Kim
  • , Jae Hyoung Park
  • , Jong Won Chung
  • , Chang Gyu Park
  • , Jin Won Kim
  • , Young Dae Kim
  • , Woo Jung Park
  • , Sang Hyun Kim
  • , Jae Kwan Cha
  • , Cheol Ho Kim
  • , Seung Woon Rha
  • , Young Joon Hong
  • , Mi Seung Shin
  • , Seong Wook Cho
  • , Young Hee Sung
  • , Kiheon Lee
  • , Jae Myung Yu
  • , Dong Ryeol Ryu
  • , Sungwook Yu
  • Tae Jin Song, Bon D. Ku, Sin Gon Kim, Hwan Cheol Park, Deok Kyu Cho, Byung Su Kim, Seong Woo Han, Sung Ji Park, Gyung Min Park, Kyoo Rok Han

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Methods: Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24–48. Secondary endpoints were assessed at weeks 24–48 and included changes in BP and LDL-C levels from baseline; the proportion of patients who achieved treatment goals who were initially classified as uncontrolled at baseline; changes and percent changes in lipid parameters; changes in both BP and LDL-C levels among patients who reached treatment goals who were followed for more than 24 weeks; and the overall safety profile. Results: A total of 5476 patients were enrolled, and 4411 patients comprised the effectiveness evaluation set. The proportions of patients who reached the treatment goals for BP, LDL-C levels, and both BP and LDL-C levels were 67.93% [95% confidence interval (CI) 66.52–69.32], 80.19% [95% CI 78.85–81.49], and 58.07% [95% CI 56.43–59.7], respectively. Secondary endpoints showed statistically significant changes. Overall, the treatment was well tolerated. Conclusions: The treatment of patients with hypertension and dyslipidemia with the olmesartan/amlodipine plus rosuvastatin SPC was associated with significant decreases in SBP/DBP and LDL-C levels, and a high proportion of patients achieved the BP and LDL-C treatment goals. The finding of this study is worthwhile in that this study evaluated the effectiveness and safety in a broad patient population representative of those seen in everyday clinical practice.

Original languageEnglish
Article number308
JournalJournal of Clinical Medicine
Volume14
Issue number2
DOIs
StatePublished - Jan 2025

Bibliographical note

Publisher Copyright:
© 2025 by the authors.

Keywords

  • blood pressure
  • dyslipidemia
  • hypertension
  • low-density lipoprotein cholesterol
  • observational study
  • single-pill combination

Fingerprint

Dive into the research topics of 'A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia'. Together they form a unique fingerprint.

Cite this